Successful reduced-intensity stem cell transplantation from an HLA haploidentical 3-loci-mismatched donor on the basis of fetomaternal microchimerism in a patient with advanced acute myeloid leukemia

International Journal of Hematology

Volumn 78, Issue 1, 2003, Pages 69-72

  Uoshima, Nobuhiko ^a   Kamitsuji, Yuri ^a   Maruya, Etsuko ^b   Saji, Hiroh ^b  

^a MATSUSHITA MEMORIAL HOSPITAL   (Japan)

^b Japanese Red Cross Kanto Koshinetsu Block Blood Center   (Japan)

Author keywords

Advanced AML; HLA haploidentical 3 loci mismatched HSCT; Long term fetomaternal microchimerism; Reduced intensity conditioning

Indexed keywords

HLA ANTIGEN; METHOTREXATE; TACROLIMUS;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CASE REPORT; CLINICAL FEATURE; DISEASE SEVERITY; FEMALE; GRAFT VERSUS HOST REACTION; HLA SYSTEM; HUMAN; MICROCHIMERISM; PERIPHERAL BLOOD STEM CELL; POLYMERASE CHAIN REACTION; REMISSION; STEM CELL TRANSPLANTATION;

EID: 0041846473     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02983243     Document Type: Article

References (17)

1. Maloney S, Smith A, Furst DE, et al. Microchimerism of maternal origin persists into adult life. J Clin Invest. 1999;104:41-47.
2. Tokita K, Terasaki P, Maruya E, Saji H. Tumour regression following stem cell infusion from daughter to microchimeric mother. Lancet. 2001;358:2047-2048.
3. Maruya E, Terasaki PI, Ichinohe T, et al. Very common occurrence of long-term reciprocal feto-maternal microchimerism detected by nested PCR for HLA antigens. Hum Immunol. 2001;62(suppl 1):S104.
4. Ichinohe T, Tamaki S, Arata W, et al. Feasibility of non-T-cell-depleted blood and marrow transplantation between haploidentical family members linked with long-term feto-maternal microchimerism [abstract]. Blood. 2001;98:669a. Abstract 2804.
5. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood. 1998;91:756-763.
6. Corradini P, Tarella C, Olivieri A, et al. Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood. 2002;99:75-82.
7. Nosaka T, Ohno H, Doi S, et al. Phenotypic conversion of T lymphoblastic lymphoma to acute biphenotypic leukemia composed of lymphoblasts and myeloblasts. J Clin Invest. 1988;81:1824-1828.
8. Ogawa H, Tsuboi A, Tamaki H, et al. Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogeneic bone marrow transplantation: importance of the monitoring of minimal residual disease by WT1 assay. Bone Marrow Transplant. 1998;21:525-527.
9. Klingemann HG, Grigg AP, Wilkie-Boyd K, et al. Treatment with recombinant interferon (α-2β) early after bone marrow transplantation in patients at high risk for relapse. Blood. 1991;78:3306-3311.
10. Shaffer L, Giralt S, Champlin R, Chan KW. Treatment of leukemia relapse after bone marrow transplantation with interferon-alpha and interleukin 2. Bone Marrow Transplant. 1995;15:317-319.
11. Tamaki S, Ichinohe T, Matsuo K, et al. Superior survival of blood and marrow stem cell recipients given maternal grafts over recipients given paternal grafts. Bone Marrow Transplant. 2001;28:375-380.
12. Van Rood JJ, Loberiza FR Jr, Zhang MJ, et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood. 2002;99:1572-1577.
13. Ochiai N, Shimazaki C, Fuchida S, et al. Successful non-T-cell-depleted HLA haploidentical 3-loci mismatched hematopoietic stem cell transplantation from mother to son based the feto-maternal microchimerism. Bone Marrow Transplant. 2002;30:793-796.
14. Giralt S, Thall PF, Khouri I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631-637.
15. Martino R, Caballero MD, De la Serna J, et al. Low transplant-related mortality after second allogeneic peripheral blood stem cell transplant with reduced-intensity conditioning in adult patients who have failed a prior autologous transplant. Bone Marrow Transplant. 2002;30:63-68.
16. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after nonmyeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet. 1999;353:1755-1759.
17. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplant. Science. 2002;295:2097-2100.